湖南尔康制药股份有限公司 2024 年度监事会工作报告 2024 年度，湖南尔康制药股份有限公司（以下简称"公司"）监事会严格按照 《公司法》《证券法》《公司章程》《监事会议事规则》等相关制度的规定，本着 对公司和全体股东负责的原则，认真履行法律法规赋予的职权，对公司经营情况、 财务状况、各项决策程序以及董事、高级管理人员履职情况等方面实施监督和检 查，为公司规范运作、提升治理水平发挥了应有作用，积极维护了公司及全体股 东的合法权益。公司 2024 年度监事会工作报告如下： 一、监事会日常工作情况 2024 年，监事会共召开了 5 次会议。监事会会议的召集、召开和表决程序 符合《公司法》《公司章程》《监事会议事规则》的有关规定。监事会召开会议的 具体情况如下： | 会议届次 | 召开时间 | 议案 | 表决情况 | | --- | --- | --- | --- | | 第五届监事会第七次会议 | 2024年4月24日 | 1、《2023年度监事会工作报告》 | | | | | 2、《2023年度财务决算报告》 | | | | | 3、《关于〈2023年度利润分配预案〉的议案》 | | | | | 4、《20 ...

目 录 一、非经营性资金占用及其他关联资金往来情况的专项 审计说明…………………………………………………………第 1—2 页 二、非经营性资金占用及其他关联资金往来情况汇总表………………第 3 页 非经营性资金占用及其他关联资金往来情况的 专项审计说明 天健审〔2025〕2-298 号 湖南尔康制药股份有限公司全体股东： 我们接受委托，审计了湖南尔康制药股份有限公司（以下简称尔康制药公司） 2024 年度财务报表，包括 2024 年 12 月 31 日的合并及母公司资产负债表，2024 年度的合并及母公司利润表、合并及母公司现金流量表、合并及母公司所有者权 益变动表，以及财务报表附注，并出具了审计报告。在此基础上，我们审计了后 附的尔康制药公司管理层编制的 2024 年度《非经营性资金占用及其他关联资金 往来情况汇总表》（以下简称汇总表）。 一、对报告使用者和使用目的的限定 本报告仅供尔康制药公司年度报告披露时使用，不得用作任何其他目的。我 们同意将本报告作为尔康制药公司年度报告的必备文件，随同其他文件一起报送 并对外披露。 为了更好地理解尔康制药公司 2024 年度非经营性资金占用及其他关联资金 往来情况， ...

证券代码：300267 证券简称：尔康制药 公告编号：2025-012 湖南尔康制药股份有限公司 关于召开 2024 年年度股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、召开会议的基本情况 1、股东大会的届次：2024 年年度股东大会 2、会议召集人：董事会 3、会议召开的合法、合规性：本次股东大会会议的召开符合有关法律、行 政法规、部门规章、规范性文件和《公司章程》等规定。 4、会议召开的日期、时间 （1）现场会议时间：2025 年 5 月 16 日（星期五）下午 14:30 （2）网络投票时间：通过深圳证券交易所交易系统进行网络投票的时间为 2025 年 5 月 16 日上午 09:15-09:25、09:30-11:30，下午 13:00-15:00；通过深圳证 券交易所互联网投票系统投票的具体时间为 2025 年 5 月 16 日 9:15--15:00 期间 的任意时间。 5、会议召开方式：本次股东大会采取现场投票与网络投票相结合的方式召 开，公司股东应选择现场投票、网络投票中的一种方式，如果同一表决权出现重 复投票表决的，以第 ...

湖南尔康制药股份有限公司 证券代码：300267 证券简称：尔康制药 公告编号：2025-006 第五届监事会第十二次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 湖南尔康制药股份有限公司（以下简称"公司"）第五届监事会第十二次会 议于 2025 年 4 月 22 日以现场会议和通讯表决相结合的方式召开。本次会议的通 知于 2025 年 4 月 11 日以书面、邮件形式通知了全体监事。本次会议应参与表决 的监事 3 名，实际参与表决的监事 3 名。本次会议的通知、召开以及参会监事人 数均符合相关法律、法规、规则及《公司章程》的有关规定。 经全体监事认真审议，形成如下决议： 一、审议通过了《2024 年度监事会工作报告》 《2024 年度监事会工作报告》的具体内容详见中国证监会选定信息披露网 站。 表决结果：同意票 3 票；反对票 0 票；弃权票 0 票。 本议案需提交公司 2024 年年度股东大会审议。 二、审议通过了《2024 年度财务决算报告》 《2024 年度财务决算报告》的具体内容详见中国证监会选定信息披露网站。 表决结果：同意票 3 ...

Financial Performance - The company achieved operating revenue of CNY 1,139.61 million and a net profit attributable to shareholders of CNY -373.37 million, primarily due to decreased sales volume and prices of pharmaceutical intermediates and composite excipients [3]. - The company's operating revenue for 2024 was ¥1,139,612,276.29, a decrease of 36.09% compared to ¥1,783,118,780.92 in 2023 [18]. - The net profit attributable to shareholders for 2024 was -¥373,371,435.91, representing a decline of 91.16% from -¥195,322,353.99 in 2023 [18]. - The net cash flow from operating activities increased by 12.31% to ¥166,691,706.92 in 2024, compared to ¥148,420,737.14 in 2023 [18]. - The total assets at the end of 2024 were ¥5,199,734,491.19, down 5.10% from ¥5,479,068,857.74 at the end of 2023 [18]. - The company reported a basic earnings per share of -¥0.1810 for 2024, a decrease of 91.13% from -¥0.0947 in 2023 [18]. - The company experienced a significant decline in net profit after deducting non-recurring gains and losses, with a figure of -¥368,820,598.49 for 2024, down 59.24% from -¥231,617,811.86 in 2023 [18]. - Total revenue for 2024 was ¥1,139,612,276.29, a decrease of 36.09% compared to ¥1,783,118,780.92 in 2023 [53]. - The pharmaceutical sector generated ¥1,107,309,520.33, accounting for 97.16% of total revenue, down 36.11% from ¥1,733,220,265.90 in 2023 [53]. - Direct sales contributed ¥1,095,605,767.52, representing 96.14% of total revenue, a decline of 37.85% from ¥1,762,856,454.62 in 2023 [54]. Market Trends - The pharmaceutical manufacturing industry in China reported a total revenue of CNY 2,529.85 billion, remaining stable year-on-year, with a total profit of CNY 342.07 billion, down 1.1% from the previous year [4]. - The lithium battery cathode material market in China saw a shipment volume of 3.35 million tons, representing a year-on-year growth of 35% [5]. - The total installed capacity of new energy vehicle power batteries in China increased by 41.5% year-on-year, with sales growing by 28.4% [5]. - In 2024, China's new energy vehicle sales reached 12.866 million units, a year-on-year increase of 35.5%, with a market share of 40.9% [29]. - The total installed capacity of power batteries for new energy vehicles in China grew by 41.5% year-on-year in 2024, while sales increased by 28.4% [29]. - The shipment volume of energy storage lithium batteries in China increased by 64% year-on-year in 2024 [31]. Company Strategy and Operations - The company plans to further integrate and optimize resource allocation to strengthen traditional businesses and enhance the development of new energy materials [5]. - The company is focusing on enhancing innovation capabilities and increasing R&D investment to adapt to the evolving pharmaceutical landscape [27]. - The company is focusing on the upstream layout of the lithium carbonate industry chain, particularly in lithium mining [36]. - The company is actively involved in the formulation and revision of pharmaceutical excipient standards in the Chinese Pharmacopoeia [35]. - The company is focusing on upstream lithium resource development, enhancing its competitive edge in the new energy materials sector [43]. - The company has implemented a "sales-driven production" model to optimize production planning and inventory management [39]. - The company is actively responding to rising raw material prices by increasing stockpiling and adjusting procurement strategies [40]. - The company is exploring new internet-based marketing and operational models to improve product visibility and market capacity [42]. - The company is enhancing comprehensive budget management to analyze past performance and future market trends, aiming for effective budget assessment and strict execution [93]. - The company is implementing lean cost reduction activities focusing on key areas such as procurement, production, sales, logistics, and management to lower production costs and management expenses [93]. Research and Development - The company has obtained 13 patents during the reporting period, including 2 invention patents and 11 utility model patents [44]. - The company has a strong commitment to research and development, aiming to innovate and improve product offerings [117]. - The company aims to obtain drug registration certificates for several new products, enhancing its product structure [66]. - The company is leveraging AI technology to enhance research and development in pharmaceutical excipients, aiming for a transition from "function provider" to "efficacy enabler" in the industry [92]. Environmental and Social Responsibility - The company invested a total of 11.24 million yuan in environmental protection and related taxes in 2024 [148]. - The company has established a wastewater treatment plant with a daily capacity of 900 tons, operating normally with no exceedances reported [148]. - The company has implemented a comprehensive environmental monitoring plan, with data uploaded monthly to the national pollution source monitoring system [148]. - The company donated pharmaceuticals valued at 4.063 million yuan to support health initiatives in July 2024 [151]. - The company emphasizes employee welfare by providing diverse cultural and recreational facilities, including gyms and sports courts [150]. Governance and Management - The company emphasizes the importance of independent directors, ensuring they fulfill their duties independently and protect the interests of all shareholders, particularly minority shareholders [104]. - The company has established a transparent performance evaluation and incentive mechanism for senior management, ensuring compliance with relevant laws and regulations [105]. - The company maintains a complete and independent financial accounting system, with no shared bank accounts with controlling shareholders, ensuring financial independence [107]. - The company has a dedicated investor relations team that actively engages with investors through various communication channels, enhancing transparency and trust [105]. - The company has established an internal control system to mitigate operational risks and improve governance, emphasizing compliance and internal audit [137]. Shareholder Information - The total number of shares is 2,062,604,870, with 31.04% being restricted shares [187]. - The controlling shareholder is Shuai Fangwen, holding 41.38% of the shares, totaling 853,574,906 shares, with 640,181,179 shares under lock-up conditions [193]. - The top ten shareholders include individuals and entities with a combined holding of over 80% of the total shares, indicating a concentrated ownership structure [194]. - The company has not experienced any changes in its controlling shareholder during the reporting period [195]. - The company has not engaged in any repurchase transactions among the top ten shareholders during the reporting period [194].

Financial Performance - The company's revenue for Q1 2025 was ¥353,547,866.17, representing a 28.19% increase compared to ¥275,789,340.20 in the same period last year[4] - Net profit attributable to shareholders reached ¥28,112,585.22, a significant increase of 868.91% from ¥2,901,461.74 year-on-year[4] - The net profit after deducting non-recurring gains and losses was ¥24,709,317.94, up 839.24% from a loss of ¥3,342,539.14 in the previous year[4] - The company's basic earnings per share rose to ¥0.0136, an increase of 871.43% compared to ¥0.0014 in the same period last year[4] - Total operating revenue for the current period reached ¥353,547,866.17, a significant increase of 28.1% compared to ¥275,789,340.20 in the previous period[19] - Net profit attributable to the parent company was ¥28,112,585.22, compared to ¥2,901,461.74 in the previous period, marking a substantial increase[20] - Operating profit for the current period was ¥26,228,298.64, up from ¥838,832.93 in the previous period, indicating strong operational performance[20] - The company reported a total comprehensive income of ¥12,391,421.98, compared to -¥34,221,597.97 in the previous period, showing a recovery in overall performance[20] - The basic and diluted earnings per share were both ¥0.0136, up from ¥0.0014 in the previous period, indicating improved profitability[20] Cash Flow and Assets - The net cash flow from operating activities was negative at -¥4,148,506.90, a decline of 138.77% compared to ¥10,699,220.82 in the same period last year[4] - Cash and cash equivalents at the end of the period totaled ¥497,470,142.04, an increase from ¥469,743,222.10 at the end of the previous period[24] - The company's cash and cash equivalents decreased to RMB 686,061,848.21 from RMB 698,537,949.74[17] - The total assets at the end of the reporting period were ¥5,124,329,676.91, a decrease of 1.45% from ¥5,199,734,491.19 at the end of the previous year[4] - Total liabilities and equity amounted to ¥5,124,329,676.91, a decrease from ¥5,199,734,491.19 in the previous period[19] Investments and Expenses - The company's investment income increased by 715.04% to ¥266.11 from ¥32.65 in the previous year, mainly due to higher returns from financial product investments[11] - The cash flow from investing activities improved significantly, with a net inflow of ¥7,337.05 compared to a net outflow of -¥20,063.45 in the same period last year, marking a 136.57% increase[12] - The company experienced a 67.97% reduction in selling expenses, which decreased to ¥812.86 from ¥2,537.79 year-on-year, primarily due to lower promotional costs[10] - Research and development expenses increased to ¥9,935,801.85 from ¥8,851,765.51, reflecting the company's commitment to innovation[19] Accounts and Liabilities - The company reported a significant increase in accounts receivable, which rose by 36.51% to ¥14,085.59 from ¥10,318.19 year-on-year, attributed to increased sales revenue[9] - The company's accounts receivable increased to RMB 140,855,852.22 from RMB 103,181,869.28[17] - Total liabilities decreased to RMB 709,570,569.44 from RMB 797,540,680.70[18] - Short-term borrowings decreased to RMB 401,261,527.78 from RMB 488,198,472.23[18] - The total non-current assets decreased to RMB 3,447,614,260.36 from RMB 3,482,652,834.83[18] - The company's retained earnings increased to RMB 1,194,203,400.81 from RMB 1,166,090,815.59[18] Subsidiaries and New Ventures - The company established a wholly-owned subsidiary, Hunan Guanha Technology Co., Ltd., with a registered capital of RMB 10 million to focus on new productivity investments[15] - The company's subsidiary in Nigeria, Erkang Mining, achieved a new operating income of RMB 77.2749 million during the reporting period[15] Other Information - The first quarter report has not been audited[25] - The new accounting standards will be implemented starting in 2025[25]

湖南尔康制药股份有限公司 第五届董事会第十三次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 证券代码：300267 证券简称：尔康制药 公告编号：2025-005 湖南尔康制药股份有限公司（以下简称"公司"）第五届董事会第十三次会议 于 2025 年 4 月 22 日以现场会议和通讯表决相结合的方式召开。本次会议的通知 于 2025 年 4 月 11 日以书面、邮件形式通知了全体董事。本次会议应参与表决的 董事 7 名，实际参与表决的董事 7 名，本次会议的通知、召开以及参与人数均符 合相关法律、法规、规则及《公司章程》的有关规定。 与会董事审阅了总经理孙庆荣先生提交的《2024 年度总经理工作报告》，并 认真审议下列议案，形成如下决议： 一、审议通过了《2024 年度董事会工作报告》 公司独立董事王军文先生、蒋悟真先生、谭雪先生向董事会提交了《独立董 事 2024 年度述职报告》，独立董事将在公司 2024 年年度股东大会上进行述职。 董事会依据独立董事出具的《独立董事关于独立性自查情况的报告》，编写 了《董事会关于独立董事独立性情况的专项报 ...

证券代码：300267 证券简称：尔康制药 公告编号：2025-007 湖南尔康制药股份有限公司 关于 2024 年度利润分配预案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次利润分配预案：不派发现金红利，不送红股，不以资本公积金转增 股本； 2、本次利润分配预案将以《关于〈2024 年度利润分配方案〉的议案》提交 公司 2024 年年度股东大会审议。 一、审议程序 湖南尔康制药股份有限公司（以下简称"公司"）于 2025 年 4 月 22 日召开第 五届董事会第十三次会议、第五届监事会第十二次会议，分别审议通过了《关于 〈2024 年度利润分配预案〉的议案》，公司 2024 年度不派发现金红利，不送红 股，不以资本公积金转增股本。本次利润分配预案将以《关于〈2024 年度利润分 配方案〉的议案》提交公司 2024 年年度股东大会审议。 根据《公司法》《公司章程》相关规定，根据公司 2024 年度实际盈利情况， 为保障公司日常生产经营及战略发展需求，维持稳健的财务状况，防范潜在风险， 更好地维护公司及全体股东的长远利益，公司拟定 ...

湖南尔康制药股份有限公司 2024 年年度业绩预告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、本期业绩预计情况 1、业绩预告期间： 证券代码：300267 证券简称：尔康制药 公告编号：2025-003 | 项目 | 本报告期（2024 | 年 1-12 | 月） | 上年同期（2023 年 | 1-12 | 月） | | --- | --- | --- | --- | --- | --- | --- | | 归属于上市公司 | 亏损：29,000 | 万元—39,000 | 万元 | 亏损：19,532.24 | 万元 | | | 股东的净利润 | | | | | | | | 扣除非经常性损 | 亏损：29,645 | 万元—39,645 | 万元 | 亏损：23,161.78 | 万元 | | | 益后的净利润 | | | | | | | 二、业绩预告预审计情况 2024 年 01 月 01 日-2024 年 12 月 31 日 2、预计的业绩：亏损 本期业绩预告相关的财务数据未经注册会计师审计。公司已就业绩预告有关 事项与年报审计会计师事务所进 ...

证券代码：300267 证券简称：尔康制药 公告编号：2024-030 湖南尔康制药股份有限公司 2024 年第一次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会未出现否决议案的情形。 2、本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 1、召集人：公司董事会 （1）出席会议的总体情况 参加会议的股东及股东授权代表共 392 名，代表股份 1,010,847,742 股,占公 司总股份的 49.0083％。 3、召开时间： 现场会议时间：2024 年 12 月 20 日（星期五）下午 14：30 网络投票时间： （1）通过深圳证券交易所交易系统进行网络投票的时间为 2024 年 12 月 20 日上午 09:15-09:25、09:30-11:30，下午 13:00-15:00； （2）通过深圳证券交易所互联网投票系统投票的具体时间为 2024 年 12 月 20 日 9:15--15:00 期间的任意时间。 4、股权登记日：2024 年 12 月 13 日（星期五） 5、现场会议召 ...